NMP22在膀胱肿瘤早期诊断中的意义

Value of NMP22 for early diagnosis of bladder cancer

目的探讨核基质蛋白22(NMP22)在膀胱早期诊断中的作用。方法采用临床流行病学研究方法,检测门诊血尿病人尿液中NMP22含量。结果以美国FDA的诊断参考值10u/ml为标准,本次研究的敏感性为97%,特异性为67%。膀胱肿瘤患者NMP22明显高于正常人,且随着膀胱癌病理分级和临床分期的增加,NMP22含量亦随之增加(P<O.001)。结论NMP22检测技术具有敏感性高、无创伤、可定量分析等优点,可以作为早期诊断膀胱肿瘤的一个指标。

Objective To evaluate the clinical value of NMP22 for early diagnosis of bladder cancer （BC）.Methods The study of clinical epidemiology was carried out.The level of NMP22 was measured in the urine of 587 patients with hematuria in outpatient service.Results According to the diagnosis standard of USA FDA（10u/ml）,the sensitivity and specificity of NM P22 for diagnosis of bladder cancer was 97% and 67% ,respectively.The level of NM P22 was elevated with the increase of pathological grade and stage （P〈 0.001）. Conclusion Urinary NM P22 is a simple ,noninvasive ,sensitive test for the early diagnosis of bladder cancer.